Abstract: A benzylamine derivative has a structure represented by the following formula (1): In a method for optical resolution of the benzylamine derivative, optically active mandelic acid is used as an optical resolving agent. In an optical resolution step in a production method of the optically active benzylamine derivative, an optically active (S)-benzylamine derivative represented by the formula (3) is precipitated as (S)-mandelic acid salt from a solution containing the benzylamine derivative and (S)-mandelic acid: wherein Ar represents an aryl group that has 6 to 15 carbon atoms and may have a substituent, and *1 represents an asymmetric carbon atom.

Abstract: A monoclonal antibody which recognizes abnormal type prion protein alone is disclosed. By the present invention, an anti-abnormal type prion monoclonal antibody whose corresponding antigen is an abnormal type prion protein, and which does not substantially react with normal type prion protein was first provided. Since the corresponding antigen of the monoclonal antibody according to the present invention is the naturally occurring abnormal type prion protein, measurement of the abnormal type prion protein may be attained with high sensitivity.

Abstract: It is intended to provide a drug which is efficacious in treating a prion disease and has a high safety. A remedy for a prion disease which contains a mesenchymal stem cell as the active ingredient and a method of producing the same. A remedy for a prion disease which contains a mesenchymal stem cell, in particular, a mesenchymal stem cell having an anti-prion antibody gene transferred thereinto as the active ingredient and a method of producing the same. These remedies can not only prevent the progress of a prion disease but also contribute to the recovery of nerve dysfunction caused by the disease.

Abstract: A monoclonal antibody which enables to distinguish the abnormal type prion from the normal type prion, as well as production process thereof, is disclosed. The anti-abnormal type prion monoclonal antibody of the invention reacts with abnormal type prion by antigen-antibody reaction but does not substantially react with normal type prion by antigen-antibody reaction. The anti-abnormal type prion monoclonal antibody of the invention may be obtained by immunizing an animal with an immunogen including a peptide containing a plurality of regions in the abnormal type prion, which regions are discontinuous each other in primary amino acid sequence of the abnormal type prion.

Abstract: An immunoassay method of the HIV-1p24 antigen by sandwich method, using at least one polyclonal antibody recognizing the HIV-1p24 antigen and at least two monoclonal antibodies recognizing the HIV-1p24 antigen, is provided together with a reagent therefor, to establish more highly sensitive assay of the HIV-1p24 antigen than conventionally.

Abstract: A hemoglobin sampler for use with stool samples for clinical tests and diagnoses of the digestive tract diseases in mass screening, etc. by securely sampling and collecting occult hemoglobin with water content from the stool samples without being hindered by the undigested solid content of stools. The sampler has a core member consisting of a porous fiber bundle made up of a plural number of synthetic fibers bundled in the longitudinal direction thereof, a rod of a suitable length provided with a thermosetting synthetic resin sheath at the outer periphery of the core, one end of the rod forming a sample absorbing member with a suitable surface area and small diameter made up of the above mentioned porous fiber bundle. The sampler can quantitatively sample occult hemoglobin with water from stool samples of various properties, thereby offering an easy sample method for the subject and stable specimen for tests.